Purpose The purpose was to compare hepatic arterial phase (HAP) respiratory motion artifact (RMA) between gadoxetate, gadobutrol, gadopentetate, and gadobenate. Materials/methods Two hundred cases of each gadolinium agent were included. RMA was assigned using 5-point Likert scale (1=no motion, 5=extreme motion) on precontrast and HAP. RMA increase (increase ≥1 on HAP from precontrast) was the outcome in logistic regression. Results Odds of RMA increase for gadoxetate were 5.5 (P<.001), 3.6 (P=.034), and 9.5 (P<.001) times higher than gadobutrol, gadopentetate, and gadobenate, respectively. Gadolinium volume and dose were not independent predictors of RMA increase. Conclusion Gadoxetate has increased odds of RMA compared with other gadolinium agents; tight contrast bolus is not a contributor.
- Hepatic arterial phase
- Respiratory motion artifact
- Transient respiratory motion
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging